Results 151 to 160 of about 593,452 (264)

Immune-Related Adverse Events of Cemiplimab Therapy in Advanced Cervical Cancer-Data from the Polish-Czech Cervical Cancer Immunotherapy Group (PCCIG-01) with a Review of the Literature. [PDF]

Antibodies (Basel)
Łupkowski R, Górniak K, Lisik-Habib M, Burchardt E, Mądry R, Szarszewska M, Gabalewicz K, Pyszak D, Bretova P, Maćkowiak-Matejczyk B, Sawczuk W, Łączyńska-Madera M, Klasa-Mazurkiewicz D, Gawlik-Urban A, Michalik M, Borysiewicz Z, Iwańska E, Puskulluoglu M, Blecharz P, Pacholczak-Madej R.   +19 more
europepmc   +1 more source

The Poland experiment [PDF]

Science
openaire   +3 more sources

Digital innovation for a greener future: the role of artificial intelligence in Europe's biofuel transition

Biofuels, Bioproducts and Biorefining, EarlyView.
Abstract This study investigates the relationship between artificial intelligence (AI) development and biofuel production using a balanced panel dataset of 12 European Union (EU) countries over the 2008–2024 period. Employing feasible generalized least squares (FGLS) estimation with distributed lag specifications, the analysis controls for Renewable ...
Tufan Sarıtaş, Emin Ahmet Kaplan, Yasin Büyükkör, Alper Aslan   +3 more
wiley   +1 more source

Shifting Epicenters: The Dynamic Regional Dispersal of SARS-CoV-2 Omicron in Poland. [PDF]

Viruses
Horecki M, Serwin K, Parczewski M.
europepmc   +1 more source

Switching disease‐modifying therapies in patients with spinal muscular atrophy: A systematic review on effectiveness outcomes

British Journal of Clinical Pharmacology, EarlyView.
With multiple disease‐modifying therapies now available, treatment switching has become an important clinical consideration in the management of spinal muscular atrophy (SMA). While some switches are prompted by suboptimal clinical response, more commonly they are driven by treatment burden, convenience, or adverse events.
Andrej Belančić, Elvira Meni Maria Gkrinia, Patrick Eustaquio, Andrea Katrin Faour, Dinko Vitezić   +4 more
wiley   +1 more source

Corrigendum to "Obinutuzumab induction and maintenance in patients with Waldenström macroglobulinaemia: an open-label, single-arm phase 2 study" EClinicalMedicine. 2025 Jul 25:86:103383. [PDF]

EClinicalMedicine
Wróbel T, Kalicińska E, Zaucha JM, Morawska M, Giannopoulos K, Jamroziak K, Lech-Marańda E, Taszner M, Szeremet A, Małecki B, Druzd-Sitek A, Łojko-Dankowska A, Dytfeld D.   +12 more
europepmc   +1 more source

Pentoxifylline dose finding trial in preterm neonates with suspected late onset sepsis (PTX‐trial)

British Journal of Clinical Pharmacology, EarlyView.
Aim The aim of this study (PTX‐trial) is to determine the optimal dose of pentoxifylline (PTX) in preterm neonates (gestational age < 30 weeks) with (suspected) late onset sepsis (LONS). Methods The PTX‐trial is a prospective multicentre open‐label sequential dose‐optimization study with an adapted continual reassessment method.
Serife Kurul, H. Rob Taal, Jan Mazela, Ryszard Lauterbach, Irwin K. M. Reiss, Karel Allegaert, Robert B. Flint, Sinno H. P. Simons   +7 more
wiley   +1 more source

Bottlenecks in the decentralisation of education funding in Poland

Ten years after delegating the responsibility for school management and operation maintenance to local governments, the education funding system in Poland still faces open challenges of fundamental importance.
Herbst, Mikolaj
core  

When protein stability drives tumor progression. [PDF]

Cent Eur J Immunol
Tabarkiewicz J, Niedźwiedzka-Rystwej P, Tynecka M, Eljaszewicz A.   +3 more
europepmc   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source